0QNA Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0QNA from our risk checks.
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 41.90 |
| 52 Week High | CHF 47.75 |
| 52 Week Low | CHF 32.20 |
| Beta | 0.74 |
| 11 Month Change | -6.26% |
| 3 Month Change | -6.37% |
| 1 Year Change | 19.37% |
| 33 Year Change | 12.44% |
| 5 Year Change | -19.11% |
| Change since IPO | -64.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QNA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 5.7% | 1.5% | 2.2% |
| 1Y | 19.4% | -17.9% | 8.8% |
Return vs Industry: 0QNA exceeded the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0QNA exceeded the UK Market which returned 8.3% over the past year.
Price Volatility
| 0QNA volatility | |
|---|---|
| 0QNA Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QNA has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0QNA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 156 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections.
Basilea Pharmaceutica AG Fundamentals Summary
| 0QNA fundamental statistics | |
|---|---|
| Market cap | CHF 510.30m |
| Earnings (TTM) | -CHF 652.00k |
| Revenue (TTM) | CHF 149.02m |
3.4x
P/S Ratio-782.7x
P/E RatioIs 0QNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QNA income statement (TTM) | |
|---|---|
| Revenue | CHF 149.02m |
| Cost of Revenue | CHF 124.90m |
| Gross Profit | CHF 24.12m |
| Other Expenses | CHF 24.78m |
| Earnings | -CHF 652.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 16.19% |
| Net Profit Margin | -0.44% |
| Debt/Equity Ratio | 570.0% |
How did 0QNA perform over the long term?
See historical performance and comparison